Journal of International Psychiatry

Abstract Objective: To investigate the relationship between serum Aβ1-42, NLRP3 and P-Tau181 and cognitive function in patients with Alzheimer’ s disease. Methods: The data of 132 patients with Alzheimer’ s disease in the hospital were selected as AD group, and 120 subjects with physical examination during the same period were included in healthy group. Montreal Cognitive Assessment (MoCA) and Clinical Dementia Rating (CDR) were used to assess the cognitive function of the two groups. According to the MoCA score, patients in the AD group were divided into mild group, moderate group and severe group. The baseline data and levels of serum factors [β-amyloid protein (Aβ1-42), nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3), phosphorylated tau-181 protein (P-Tau181)] were compared between the two groups. . Results: There were no significant differences between AD group and healthy group in terms of gender, age, body mass, course of disease, hypertension, diabetes mellitus, hyperlipidemia and smoking history (P<0.05). The levels of serum Aβ1-42, NLRP3 and P-Tau181 of AD group were significantly higher than that of healthy group (P<0.05). The levels of serum Aβ1-42, NLRP3 and P-Tau181 in severe group were significantly higher than those in moderate group and mild group (P<0.05). Conclusion: Serum Aβ1-42, NLRP3 and P-Tau181 in patients with AD are related to the occurrence and development of the disease, and their expression levels are positively correlated with the degree of cognitive impairment in patients.

Key Words Alzheimer’ s disease; Cognitive function; β-amyloid protein; Nucleotide binding oligomerization domain-like receptor protein 3; Phosphorylated tau-181 protein; Correlation